doi: 10.1038/s41392-022-01102-y 6 KamraniAHosseinzadehRShomaliNHerisJAShahabiPMohammadinasabRet al
Currently enrolled in phase 2 clinical trials, MariTide is expected to conclude by late 2024, with future studies in phase 3 focusing on obesity and its associated conditions, including heart, liver, and kidney diseases
Farah and Puthoff address the reasons behind historical cover-ups, the implications of disclosure for technology and society, and the bipartisan political momentum building around UAP investigation
Acarbose Even though acarbose has been shown to produce changes in the composition of the microbiota, dysbiosis and intestinal bacterial overgrowth are not the pathophysiologic mechanisms involved in the bloating and diarrhea associated with the administration of the drug.6,7,6064 The acarbose-associated alteration of the microbiota is an increase in the density of the genus Lactobacillus and the genus Bifidobacterium, a composition of the microbiota that is protective for gastrointestinal symptomatology.64,65 Despite the protective modification in the microbiota, acarbose is associated with gastrointestinal adverse effects by producing poor disaccharide, oligosaccharide, and polysaccharide absorption
